Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 200,000 shares at $53.96 ($10.8M) on 2023-09-18, disclosed to the SEC on 2023-09-19.
Scheduled sale ($10.8M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.55 | 27,468 | $1.5M | 13.6% |
| 2 | $53.55 | 27,468 | $1.5M | 13.6% |
| 3 | $53.96 | 28,119 | $1.5M | 14.1% |
| 4 | $53.96 | 28,119 | $1.5M | 14.1% |
| 5 | $54.17 | 44,413 | $2.4M | 22.3% |
| 6 | $54.17 | 44,413 |
| $2.4M |
| 22.3% |
| Total | $53.94 avg | 200,000 | $10.8M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |